Ibuprofen intravenous - Cumberland Pharmaceuticals

Drug Profile

Ibuprofen intravenous - Cumberland Pharmaceuticals

Alternative Names: Amelior; Caldolor; Ibuprofen injection

Latest Information Update: 15 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cumberland Pharmaceuticals
  • Developer Al-Nabil; Alveda Pharma; Cumberland Pharmaceuticals; DB Pharm Korea; GerminMED; Grifols; Piramal Critical Care; PT SOHO Industri Pharmasi; PT. ETHICA Industri Farmasi; Sandor Medicaids; Seqirus
  • Class Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Fever; Pain

Most Recent Events

  • 24 Mar 2016 Launched for Pain (In adolescents, In children, In infants) in USA (IV)
  • 24 Mar 2016 Launched for Fever (In adolescents, In children, In infants) in USA (IV)
  • 14 Mar 2016 Cumberland Pharmaceuticals and Laboratorios Grifols enter into a licensing agreement to develop Caldolor® in Spain, Portugal, and the majority of South America (Cumberland Pharmaceuticals, Form 10-K, March 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top